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Abstract
Background Inflammatory autoimmune diseases are chronic diseases that often affect women of childbearing age. Therefore, 
detailed knowledge of the safety profile of medications used for management of inflammatory autoimmune diseases during 
pregnancy is important. However, in many cases the potential harmful effects of medications (especially biologics) during 
pregnancy (and lactation) on mother and child have not been fully identified.
Objective Our aim was to update the data on the occurrence of miscarriages and (major) congenital malformations when 
using biologics during pregnancy based on newly published articles. Additionally, we selected several different secondary 
outcomes that may be of interest for clinicians, especially information on adverse events in the use of a specific biologic 
during pregnancy.
Material and Methods A search was conducted from 1 January 2015 until 4 July 2019 in Embase.com, Medline Ovid, Web 
of Science, Cochrane CENTRAL, and Google Scholar with specific search terms for each database. Selection of publications 
was based on title/abstract and followed by full text (double blinded, two researchers). An overview was made based on out-
comes of interest. References of the included publications were reviewed to include and minimize the missing publications.
Results A total of 143 publications were included. The total number of cases ranged from nine for canakinumab to 4276 
for infliximab. The rates of miscarriages and major congenital malformations did not show relevant differences from those 
rates in the general population.
Conclusion Despite limitations to our study, no major safety issues were reported and no trend could be identified in the 
reported malformations.
Key Points 
The rates of miscarriages and major congenital malfor-
mations after exposure to biologics during pregnancy do 
not deviate from these rates in the general population.
It is likely that use of adalimumab, certolizumab pegol, 
and etanercept is safe during pregnancy.
Data on risks of using abatacept, anakinra, canakinumab, 
golimumab, rituximab, tocilizumab, ustekinumab, and 
vedolizumab are scarce.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 5-020-01376 -y) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Chronic inflammatory diseases such as rheumatoid arthri-
tis (RA), psoriatic arthritis (PsA), ankylosing spondylitis 
(AS), inflammatory bowel disease (IBD), and psoriasis, 
are common in women of childbearing age [1–3].
Active disease may not only be harmful for the mother, 
but also carries a risk for the fetus. There is an overlap 
between biologics used for the management of rheumatic, 
gastroenteric, and dermatologic autoimmune diseases. Even 
though biologics have shown efficacy in keeping the dis-
ease under control, their safety profile in pregnant women 
is still uncertain. Based on the mode of action, biologics 
are classified into tumor necrosis factor (TNF)-α inhibi-
tors and non-TNF biologics. At present, pregnancy registry 
data have become available for only four TNF-α inhibitors 
(adalimumab, certolizumab pegol, etanercept, and inflixi-
mab) [4–7]. For other biologics (non-TNF-α inhibitors) and 
biosimilars used during pregnancy in autoimmune diseases 
there is still insufficient information on the occurrence of 
adverse events such as congenital malformations (CMs). As 
a precaution, the use of such medications during pregnancy 
is discouraged before acquisition of reassuring results from 
a pregnancy registry. In addition, unintentional exposure to 
medication(s) may also occur in cases of unplanned preg-
nancies. Accordingly, knowledge on the safety of medication 
during pregnancy is of great importance [8–10].
In the pre-authorization period, pregnant women are 
excluded from randomized clinical trials (RCTs) for ethi-
cal reasons. After authorization, the main available data 
are collected prospectively by different registries or ret-
rospectively from healthcare databases, and in some cir-
cumstances published as case reports. Summarizing the 
available data in a systematic review can be helpful to gain 
a better perspective on the use of different biologics during 
pregnancy and lactation.
The European League Against Rheumatism (EULAR) 
have published a systematic review on this topic (search 
period 2008–2015) [8]. However, it is important to provide 
up-to-date knowledge based on published data after this 
period. In this regard, a meta-analysis that included data 
from 24 studies was published by Tsao et al., in which the 
authors pooled the available evidence to assess the impact 
of biologic therapy during pregnancy [11]. This current sys-
tematic review aimed to update the data on the impact of 
maternal exposure to biological therapy by focusing specifi-
cally on miscarriages and (major) CMs. Furthermore, in this 
systematic review, each biologic is considered separately and 
the pattern of reported CMs is documented. Other clinically 
relevant outcomes such as vaccination response, detectable 
drug levels during different stages of pregnancy, infections, 
and stillbirths are also investigated.
Thus the aim of this systematic review was to update the 
data on miscarriages and (major) CMs separately for each 
biologic used in inflammatory autoimmune diseases, based 
on newly published articles since 2015. Due to overlap in 
indications of biologics between rheumatic diseases, IBD, 
and psoriasis, studies on the use of biologics in IBD and 
psoriasis were also included.
2  Materials and Methods
A PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) [11] guideline was followed 
in the design of this study.
2.1  Protocol and Registration
This systematic review was registered retrospectively 
at PROSPERO under the code CRD42019135316. The 
recorded protocol was not provided prospectively in PROS-
PERO [12].
2.2  Information Sources and Search Strategy
A systematic search was conducted in the following data-
bases: Embase.com, Medline Ovid, Web of Science, 
Cochrane CENTRAL, and Google Scholar. The search strat-
egy was designed and conducted by an experienced librar-
ian with input from the study’s main investigator (NG). The 
Medical Subject Heading (MeSH) terms used for each data-
base are detailed in the Electronic Supplementary Material 
(ESM). The search only included articles published from 1 
January 2015 until 4 July 2019.
2.3  Study Selection and Data Collection Process
All relevant citations were saved in a bibliographic reference 
manager (Endnote × 9 version, Thomson Reuters, Philadel-
phia, PA, USA) and duplicates were removed. Titles and 
abstracts were analyzed according to inclusion and exclu-
sion criteria (see Box 1). Additional citations were identified 
from the reference list of all previously selected articles. The 
selection process was conducted by two researchers (NG and 
IC) with a medical background, by reviewing the titles and 
the abstracts, independently. Discrepancies were resolved 
through discussions at consensus meetings.
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2.4  Data Items, Outcomes, and Prioritization
Primary outcomes were defined as:
1. Miscarriages Spontaneous loss of pregnancy before 
24 weeks of gestation, also known as spontaneous abor-
tion [13];
2. Major CMs Conditions caused by failure of a particular 
body site or body system to develop correctly during 
the antenatal period, which had medical implications, 
required surgical repair, or were life threatening. (The 
list of malformations considered as major can be found 
in Supplementary Table 1) [14].
Other variables for which data were sought were catego-
rized in two groups:
1. Maternal-related outcomes:
(a) Ectopic pregnancies Any condition character-
ized by implantation of the embryo outside the 
endometrium and endometrial cavity during preg-
nancy;
(b) Induced abortions The removal of an embryo or 
fetus from the uterus at a stage of pregnancy when 
it is deemed incapable of independent survival; at 
any time between conception and the 24th week 
of gestation (GW);
(c) Pregnancy-related hypertension Gestational 
hypertension, pre-eclampsia, and eclampsia;
(d) Premature rupture of membranes Spontaneous 
rupture of fetal membranes before the onset of 
labor;
(e) Emergent caesarian sections Unplanned caesarian 
section (C-section) due to maternal/fetal condi-
tion; other types/uncategorized C-sections were 
not considered in the results;
Box 1. Inclusion and exclusion criteria  
Following publicaons were included: 
- Cohort studies, case-control studies, case reports, registry studies, pharmacological signaling studies and abstracts 
(RCTs are not included in this study, as all the invesgated biologics are registered before 01/01/2015)
- Full text in English, German, Dutch, French, Spanish or any other languages, provided that an English abstract was 
available
- Publicaons published aer 01/01/2015 
Following publicaons were excluded: 
- Duplicate arcles  
- Meta-analysis, literature review arcles, editorial arcles, animal/in-vitro studies, comments, research leers  
- Arcles without an English abstract 
- Studies on diseases other than rheumatoid, gastroenterological and dermatologic autoimmune diseases  
- Arcles that do not provide informaon about the outcome of the pregnancies exposed to biologics 
- Studies with same populaon source as another included arcle (the most recent arcle was chosen to be included 
in these situaons)
- Only Paternal exposure 
(f) Flare-up during pregnancy/post-partum Active 
disease during pregnancy/during 6 months after 
delivery;
(g) Detectable drug concentration in breast milk
2. Child-related outcomes:
(a) Minor CMs Conditions caused by failure of a par-
ticular body site or body system to develop cor-
rectly during the antenatal period, which pose no 
significant health problem in the neonatal period 
and tend to have limited social or cosmetic conse-
quences for the affected individual, were consid-
ered minor CMs;
(b) Live births The complete expulsion or extrac-
tion from the mother of a baby, irrespective of 
the duration of the pregnancy, which, after such 
separation, breathes or shows any other evidence 
of life;
(c) Still birth A baby born with no signs of life at or 
after 24 weeks of gestation;
(d) Neonatal death Death during the first 28 days of 
life;
(e) Low birth weight When the infant was born weigh-
ing less than 2500 g;
(f) Pre-term birth When the infant was born before 
37 weeks of gestation;
(g) Small for gestation age (SGA) When birth weight 
was below − 2 standard deviations of the mean 
or below the 10th percentile according to local 
intrauterine growth charts;
(h) Adequate vaccination response Measured by labo-
ratory findings on immune response after vaccina-
tion;
(i) Adverse drug reactions (ADRs) related to vaccinations;
(j) Allergies;
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(k) Eczema;
(l) Serious/opportunistic infections Infections 
that required medical intervention/hospitali-
zation;
(m) Anti-drug antibodies at birth in the newborn;
(n) Detectable drug levels
 (i) in cord blood
 (ii) in infant’s blood at birth
 (iii) during first 6, 9, and 12 months of life;
(o) Abnormal development Physical/psychologi-
cal developmental delay in children.
ther variables for which data were sought were categorized 
in two groups.
Data that did not meet mentioned definitions were not 
considered in the final results.
2.5  Risk of Bias in Individual Studies
The quality of the studies was scored by awarding points 
in each domain following the guidelines of the New-
castle–Ottawa Scale (NOS) for either cohort studies or 
case–control studies. The NOS assigns up to a maximum 
of nine points for the least risk of bias in three domains: (1) 
selection of study groups (four points); (2) comparability 
of groups (two points); and (3) exposure or outcome (three 
points) for case–control and cohort studies (see Supplemen-
tary Table 2, ESM) [15].
2.5.1  Summary Measures
Numbers of cases occurred for each specific outcome and 
with exposure to each specific biologic were extracted from 
each article and entered into the chart.
2.5.2  Risk of Bias Across Studies
Due to heterogeneity of the data the calculated percentages 
are up to clinical interpretations and comparison of the out-
comes should be performed with caution.
2.5.3  Data Synthesis
All included articles were considered in data synthesis if 
they had reported at least one outcome for a specific bio-
logic. Percentage of occurrence for each outcome was 
calculated as cumulative number of cases divided by the 
population, for which that specific outcome was reported in 
the included publications.
2.5.4  Confidence in Cumulative Evidence
The cumulative evidence of the studies was assessed by 
GRADE scoring (The Grading of Recommendations 
Assessment, Development and Evaluation Working Group; 
[retrieved 17 September 2019]) and the score of the Oxford 
Centre for Evidence-Based Medicine (CEBM) [retrieved 17 
September 2019] [16–18].
The GRADE approach results in an assessment of the 
quality of evidence on four levels: (1) high (++++), (2) 
moderate (+++), (3) low (++), and (4) very low (+) based 
on all publications and their limitations. First a primary 
ranking of ‘high’ or ‘low’ was assigned to RCTs or obser-
vational studies (if included for the specific group of pub-
lications for one specific biologic). Then the initial ranking 
was downgraded or upgraded based on among others risk of 
bias, inconsistency, imprecision, indirectness, confounding 
in cumulative evidence based on all included publications 
for the specific biologic. It should be mentioned that the final 
score is not an average of individual scores, but a cumulative 
assessment for all the publications together, as explained 
above [16, 18].
The strength of cumulative evidence was graded using 
a 1–5 ordinal scale for CEBM, in which the lower the risk 
of confounding (bias), the further to the left the type of evi-
dence will lie in the scale. Steps were taken as for GRADE 
score and final score was assigned to the cumulative evi-
dence from all publications included for one biologic at a 
time [17].
For both the GRADE scoring and the CEBM calcula-
tions the included studies and case reports were weighted 
considering case–control studies are recommended studies 
for identifying congenital anomalies [19] followed by cohort 
studies and case reports, as they have the lowest weight. 
Abstracts scored lower than full articles, because the meth-
ods section often does not sufficiently describe the control 
group and the adjusting for confounders. The GRADE and 
CEBM scores based on these considerations are presented 
in Table 1.
3  Results
3.1  Study Selection
A total of 4823 articles were primarily extracted from the 
mentioned databases up to 4 July 2019. Selection of pub-
lications was based on title/abstract and followed by full 
text (double blinded, two researchers). 151 articles were 
excluded after reading the full text based on the following 
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases
reasons: duplicate articles (including abstracts/posters that 
had published full texts) (n = 69), information on the out-
come of the pregnancies exposed to biologics not provided 
(n = 64), studies with the same population source as another 
included article (n = 13), in vitro studies (n = 3), only pater-
nal exposure was investigated (n = 1), studies on diseases 
other than intended for this article (n = 1). References of 
the included articles were screened for additional inclusion. 
Nine additional articles were added to the dataset sheets 
based on reference-screening of included articles. A total 
of 143 articles were included. The steps taken are shown 
in Fig. 1.
3.2  Study Characteristics
In total 143 publications were included. The number of pub-
lications for each biologic ranged from two (canakinumab) 
to 59 (infliximab). The references, type of publications, and 
GRADE and Oxford CEBM scores for each biologic are 
presented in Table 1.
3.3  Risk of Bias Within the Studies
The authors acknowledge the risk of information bias in 
some studies that evaluated pooled data on several biolog-
ics, without reporting the numbers of outcomes for each bio-
logic separately. The results of these studies, however, are 
described in this article as two additional categories under 
the subtitles of “TNF alpha blocker (in general, not specified 
in the full text)”and “Biologics (in general, not specified in 
the full text)”.
3.4  Results of Individual Studies and Synthesis 
of the Results
The key outcomes for each biologic are discussed below. 
To gain a better perspective regarding overall possible 
confounders, data on maternal characteristics such as dis-
ease type, co-morbidities, concomitant medication expo-
sure, presence of anti-drug antibodies in maternal serum, 
exposure during the first and all three trimesters, and rate 
of breastfeeding after delivery were calculated, if possible 
(Table 2). Outcome measures are presented in Tables 3 and 
4 for maternal- and child-related outcomes, respectively. It 
noitacifitnedI
gnineercS
ytilibigilE
dedulcnI
Publications identified through literature database searches
N = 4823
Publications after duplicate removal and screening based on 
title/abstract
N = 285
Excluded publications based on 
inclusion/exclusion criteria after reading 
title/abstract, N= 4538
Excluded publications based on 
inclusion/exclusion criteria after reading the full 
text, N= 151
Publications after screening based on full text
N =134
Publications with data on sought outcomes
N= 143
Additional articles based on reference-screening
from included atricles, N = 9
Fig. 1  Flow diagram of databases searched according to the PRISMA guidelines
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should be noted that due to heterogeneity of the data the 
calculated percentages cannot be compared.  
3.4.1  Abatacept
In total 157 maternal pregnancies were investigated in five 
articles. Outcomes regarding miscarriages were investigated 
for 153 of these pregnancies, in which 40 miscarriages were 
reported (26.1%).
Seven major CMs were reported in 88 pregnancies 
(7.9%), which included:
1. Cleft palate (n = 1)
2. Congenital aortic-anomaly (n = 1)
3. Meningocele (n = 1)
4. Pyloric stenosis (n = 1)
5. Skull malformation (unspecified) (n = 1)
6. Ventricular septal defect (VSD) (n = 1)
7. Congenital arterial malformation (n = 1) [9].
The percentage and variety of co-medication use (includ-
ing methotrexate (MTX) exposure) could not be extracted 
for the reported miscarriages from the presented data.
3.4.2  Adalimumab
A total of 2027 maternal pregnancies were described in 50 
articles. Outcomes regarding miscarriages were reported for 
180 pregnancies, in which 16 miscarriages occurred (8.9%). 
Forty-six (n = 46) major CMs were reported in 1008 preg-
nancies (4.6%). Thirteen major CMs were described as fol-
lows (the other cases did not describe explicitly the major 
CM or the major CM could not be linked to this specific 
biologic):
 1. Cleft palate (n = 1).
 2. Cleft palate, micrognathia, myopia, glaucoma and 
esophageal motility disorder (n = 1).
 3. Congenital diaphragmatic hernia and obstructive mega 
ureter (n = 1).
 4. Polydactyly (n = 1).
 5. Hexadactyly (n = 1).
 6. Hexadactyly both feet and atrial septal defect (ASD) 
(n = 1).
 7. Esophageal atresia with tracheo-esophageal fistula, 
VSD, syndactyly in both feet, peripheral pulmonary 
stenosis, persistent foramen ovale (PFO) (n = 1).
Table 1  Summary of the references and GRADE scores (confidence in cumulative evidence)
Drug Number and type of publications References GRADE CEBM
Abatacept 1 cohort, 2 register data (2 abstracts), 2 case 
reports/series (1 abstracts)
[9, 20–23] ++ 3–4
Adalimumab 19 cohorts (9 abstract), 14 register data (6 
abstract), 6 case controls (1 abstract), 11 case 
reports/series (3 abstract)
[1, 20–69] +++ 3
Anakinra 4 cohorts (1 abstract), 2 case reports/series [20, 57, 70–73] + 4
Canakinumab 1 cohort, 1 case report (1 abstract) [72, 74] + 4
Certolizumab pegol 14 cohorts (6 abstract), 10 register data (1 
abstract), 4 case controls (1 abstract), 4 case 
reports/series (3 abstract)
[1, 20, 22, 23, 31, 33, 37, 39, 40, 42, 44, 48, 54, 
55, 57, 58, 63, 64, 66, 68, 75–88]
++ 3–4
Etanercept 12 cohorts (5 abstract), 6 register data (2 abstract), 
2 case controls (1 abstract), 6 case reports/series 
(2 abstract)
[1, 20–23, 27, 33, 35, 40, 41, 44, 45, 47, 53–57, 
60, 63, 66, 68, 87, 89–91]
+++ 3
Golimumab 9 cohorts (2 abstract), 3 register data (1 abstract), 
2 case controls (1 abstract), 2 case reports/series 
(1 abstract)
[20, 22, 23, 33, 35, 40, 44, 48, 53–55, 58, 64, 66, 
68, 80]
+ 4
Infliximab 23 cohorts (11 abstract), 13 register data (2 
abstract), 3 case controls, 20 case reports/series 
(10 abstract)
[1, 20–25, 28, 31, 34–38, 40, 42–44, 46–48, 51, 
53, 55, 57, 58, 60–62, 64–68, 76, 77, 79, 80, 
92–112]
++ 3–4
Rituximab 5 cohorts (2 abstract), 3 register data (2 abstract), 1 
case reports/series (1 abstract)
[20, 22, 44, 45, 56, 57, 63, 66, 113] + 4
Tocilizumab 1 cohort, 1 register data (1 abstract), 8 case 
reports/series (3 abstract)
[22, 23, 41, 45, 114–119] ++ 3–4
Ustekinumab 4 cohorts, 3 register data (2 abstract), 15 case 
reports/series (3 abstract)
[27, 37, 44, 53, 59, 60, 64, 66, 67, 77, 80, 
120–130]
+ 4
Vedolizumab 2 cohorts (1 abstract), 1 register data, 2 case 
controls (1 abstract), 2 case reports/series (1 
abstract)
[64, 77, 131–135] + 4
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Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases
 8. ASD with left–right shunt and aneurysm, cavum sep-
tum pellucidum on both sides, hemangioma at left 
flank (n = 1).
 9. VSD and hip dysplasia (n = 1).
 10. Hemangioma right temple, umbilical hernia (n = 1).
 11. Imperforate anus (n = 1).
 12. Amniotic band sequence: talipes and amputation of 
four fingers of the right hand (n = 1).
 13. Cystic adenomatoid malformation of the right lung, 
incomplete right bundle branch block, pericardial 
effusion, PFO, persistent ductus arteriosus (PDA) and 
slight persistent pulmonary hypertension (co-medica-
tion: etanercept) (n = 1) [1, 20, 68].
Data on overall concomitant medication was available for 
278 cases. Use of one or more co-medications was reported 
for 71 of these patients (25.5%). Data on exposure to MTX 
were available for 80 cases, of which six patients (7.5%) 
were exposed to MTX.
Growth was investigated in 61 children exposed to adali-
mumab during pregnancy, of which only one primary growth 
failure due to cystic fibrosis was reported (1.6%) [43].
Adalimumab was detectable in breast milk of two patients 
from the total 21 investigated cases (9.5%), with a maxi-
mum concentration of 0.71 μg/mL seen between 12 and 24 h 
after injection. In seven cases breast milk was examined after 
7 days from the injection and it was not detectable in any of 
these cases [80].
3.4.3  Anakinra
In total 35 maternal pregnancies were investigated in six 
articles. Outcomes regarding miscarriages were investigated 
for 33 of these pregnancies, in which only one miscarriage 
was reported (3.1%, concomitant therapy was not reported 
in this case) [72]. One major CM was reported (2.9%, unilat-
eral renal agenesis and ectopic neurohypophysis, which also 
had abnormal growth due to growth hormone deficiency) 
[72]. One minor CM (a case of tied tongue after exposure to 
anakinra during pregnancy [73]) was reported among nine 
cases that were investigated for such an outcome. Data on 
overall concomitant medication was available for five cases. 
Use of one or more co-medications was reported for four of 
these patients (80.0%). MTX exposure was not reported for 
any of these patients.
Emergent C-sections were reported in two cases. One 
case because of a pathological cardiotocography (CTG) 
and premature rupture of the membranes and umbilical 
cord entanglement. The other case was a secondary emer-
gent C-section due to uterine rupture under spontaneous 
delivery [70].
3.4.4  Canakinumab
In total nine pregnancies were investigated in two articles 
[72, 74]. Outcomes regarding miscarriages were investigated 
for all of these pregnancies, in which only one miscarriage 
was reported (11.1%, at 6 weeks of pregnancy to a mother 
with refractory Cogan syndrome). Concomitant medication 
was not reported in this case [72]. No CMs were reported 
in eight live births. Data on overall concomitant medication 
(including MTX exposure) were not available.
3.4.5  Certolizumab Pegol
In total 883 maternal pregnancies were investigated in 32 
articles. Outcomes regarding miscarriages were investigated 
for 679 of these pregnancies, in which 78 miscarriages were 
reported (11.5%). Ten major CMs were reported from a total 
of 535 investigated cases (1.9%). In the article by Broms 
et al. the described major CMs were not categorized based 
on the kind of biologic used during pregnancy. Therefore, 
the one reported case of major CM for certolizumab pegol in 
this study could not be associated with the described cases 
[40]. Nine described cases in other articles could be linked 
to certolizumab pegol and were as follows (the rest of the 
cases were not described explicitly or could not be linked to 
this specific biologic):
1. Clubfeet and Hirschsprung’s disease (n = 1)
2. Anal fistula (n = 1)
3. Talipes (n = 1)
4. Vesicoureteric reflux (n = 1)
5. Cerebral ventricle dilatation (n = 1)
6. Hydronephrosis (n = 1)
7. Congenital heart disease (n = 1)
8. Accessory auricle (n = 1)
9. Polydactyly (n = 1) [75, 78].
Data on overall concomitant medication were avail-
able for 553 cases. Use of one or more co-medications was 
reported for 402 of these patients (72.7%). Data on exposure 
to MTX were available for 25 cases, of which none were 
exposed to MTX.
From the two reported cases of early membrane ruptures, 
one was due to infection [75]. The other one occurred at the 
35th week in a mother exposed to certolizumab pegol during 
the first trimester [1].
Reported infections in mothers were mainly urinary tract 
infections and upper respiratory tract infections. In one case 
pyelonephritis with septicemia at 30th GW was reported 
in a patient who was on certolizumab pegol combination 
therapy with hydroxychloroquine, sulfasalazine, and pred-
nisone [75].
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Two cases of neonatal deaths occurred in a twin preg-
nancy; one of the twins was born at 25th GW with brain 
damage and pneumo-peritoneum, the other twin was born 
at 27th GW with heart defects and passed away due to a 
gastrointestinal infection at the 8th week of age [78].
Concentration in breast milk was investigated in 13 cases. 
Certolizumab pegol was detectable in three of these cases 
with a maximum concentration of 0.29 μg/mL peak. In two 
cases breast milk was examined after 7 days following the 
injection, and it was not detectable in either case [80].
3.4.6  Etanercept
In total 1145 maternal pregnancies were investigated in 26 
articles. Outcomes regarding miscarriages were investigated 
for 359 of these pregnancies, in which 69 miscarriages were 
reported (19.2%). From 815 exposed cases during preg-
nancy, 47 major CMs were reported (5.8%). Six described 
cases are as follows (the rest of the cases were not described 
explicitly or could not be linked to this specific biologic):
1. Hypoplastic left heart and hypospadias (n = 1)
2. Agenesis of left kidney (n = 1)
3. Bilateral hydronephrosis (n = 1)
4. ASD (n = 1)
5. Wolf–Parkinson–White syndrome with heart failure 
(n = 1)
6. Omphalocele (n = 1) [55, 68].
Data on overall concomitant medication were avail-
able for 353 cases. Use of one or more co-medications was 
reported for 70 of these patients (19.8%). Data on exposure 
to MTX were available for 343 cases, in which 59 patients 
(17.2%) were exposed to MTX.
3.4.7  Golimumab
In total 31 maternal pregnancies were investigated in 16 pub-
lications. No data regarding miscarriages could be extracted 
from the presented information in these articles. No major 
CMs were reported in 13 exposures during pregnancy for 
golimumab. Data on overall concomitant therapy (including 
MTX exposure) were not available.
3.4.8  Infliximab
In total 4276 maternal pregnancies were investigated in 59 
articles. The largest amount of prospective data was reported 
from a Janssen biologics database, which reported preg-
nancy results of 1362 reported spontaneous cases, clinical 
studies, and registries [101]. Outcomes regarding miscar-
riages were investigated for 1584 of these pregnancies, in 
which 170 miscarriages were reported (10.7%).Ta
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In total 51 major CMs were reported in 1222 pregnancies 
(4.2%). Fourteen described major CMs are as follows (the 
rest of the cases were not described explicitly or could not 
be linked to this specific biologic):
 1–3. VSD (n = 3).
 4, 5. Cleft palate (n = 2).
 6, 7. Facial hemangiomata (n = 2).
 8. ASD (n = 1)
 9. Ectrodactyly (n = 1)
 10. Polydactyly (n = 1)
 11. Hydronephrosis and obstructive megaureter (n = 1)
 12. Pelviureteric junction obstruction (n = 1)
 13. Small aortic-pulmonary collateral, hypospadias, 
hepatic cyst (n = 1)
 14. Megacystis plus bilateral talipes (n = 1) [43, 68, 107–
109].
Two cases of minor CMs were reported in 94 patients 
(2.1%). This included one case of duplex kidney and one 
case of aberrant subclavian artery [136]. Data on overall 
concomitant medication were available for 461 cases. Use 
of one or more co-medications was reported for 85 of these 
patients (42.9%). Data on exposure to MTX were available 
for 221 cases, of which 36 patients (16.3%) were exposed 
to MTX.
Five hundred and forty-seven patients from a total of 
1939 (28.2%) were exposed to infliximab during the entire 
pregnancy (all three trimesters). The data on elimination 
of infliximab during pregnancy were available only from a 
pharmacokinetics (PK) study, which compared drug levels 
and its clearance during different trimesters in 22 pregnan-
cies. It was reported in this study that infliximab clearance 
decreased by 12% in the second and third trimesters [112].
The median ratio of inf liximab in cord blood to 
maternal level was 2.63 (95% confidence interval (CI), 
1.67–4.03) in 52 patients [median duration of therapy until 
23 GW (range 21–32)] [43] and 3.25 in two patients in 
another study (therapy continued until last week of gesta-
tion) [28]. In one case report in a patient under infliximab 
treatment with the dose of 10 mg/kg every 6 weeks until 
the 32th GW, the cord blood concentration was 110.1 μg/
mL. Plasma infliximab level in the mother at the time 
of delivery was 59.7 µg/mL [93]. The median ratio of 
infant to maternal drug concentration at birth was 1.97 
(95% CI 1.50–2.43) in 44 patients (18 patients and 26 
patients received last infusion before and after the 30th 
GW, respectively) [136]. In another study the median con-
centration was 7.8 μg/mL in patients who used infliximab 
until the 18th–36th weeks of gestation [51].
Infliximab was detectable in 19 patients’ breast milk 
out of a total of 29 patients, with a maximum range of 
0.15–0.74  μg/mL 24  h after infusion, detectable in 17 
samples from a total of 29 after 48 h, and detectable in five 
samples from a total of eight after 168 h (no concentrations 
were reported for samples in the last two groups). Weight-
adjusted dose was not calculated in this study [80].
Six cases from a total of 1372 (0.4%) required emergency 
C-section. One of these cases had undergone an emergency 
C-section because of placental dysfunction, in which a very 
low-birth-weight preterm infant was born [99].
There was a case report of an infant diagnosed with 
vertical transmission of disseminated histoplasmosis from 
mother at the time of delivery and through the placenta 
(authors’ conclusion: probable involvement of the central 
nervous system). The mother was taking infliximab (IBD 
indication) until the 32th GW (delivery at 35th GW) [93].
A follow-up of 533 children exposed to infliximab showed 
abnormal development in 33 of these children (6.2%). 
Descriptions of abnormal development were provided in 
three of these cases: two cases reported deviations in weight 
or height percentiles and one case of late gross motor func-
tion development, which was resolved by 20 months of age 
[43, 94, 109].
Regarding vaccination (one or more vaccinations with 
Bacillus Calmette-Guérin (BCG), rotavirus, Haemophilus 
influenzae type b (Hib), tetanus, or hepatitis B), in total 
197 cases were investigated in different publications [1, 43, 
51, 58, 62, 77, 94, 100, 109, 137]. Twenty-nine cases were 
investigated regarding response to tetanus and hepatitis B 
vaccination, of which 28 had adequate response [28, 51, 
62, 77, 100]. Adverse drug reactions were reported in six 
cases with mild reactions to rotavirus vaccination (fever, 
n = 5 and diarrhea, n = 1) in children exposed to infliximab 
during pregnancy [77].
3.4.9  Rituximab
In total 42 maternal pregnancies were investigated in nine 
articles. Outcomes regarding miscarriages were investi-
gated for 24 of these pregnancies, of which only one (4.2%) 
miscarriage was reported at 12th GW in a case exposed to 
rituximab 1 month prior to conception and MTX at the time 
of conception [113].
No major CMs were reported for 20 pregnancy cases 
expose to rituximab. Data on exposure to MTX were avail-
able for 23 cases. It was reported for five of these patients 
(21.7%).
Two cases of stillbirth were reported, which occurred 
in the same patient, with rituximab exposure at 9 and 
18 months prior to conception [113].
3.4.9.1 Tocilizumab In total 368 maternal pregnancies 
were investigated in ten articles. Outcomes regarding mis-
carriages were investigated for 361 of these pregnancies, in 
which 84 miscarriages were reported (23.3%). Data on con-
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comitant exposure to MTX for reported miscarriages were 
not available.
Eleven major CMs were reported in a total of 345 inves-
tigated pregnancies with tocilizumab (3.2%). Eight of these 
cases were described as follows:
1. Pyelectasia (n = 1)
2. Multicystic dysplasia of right kidney (n = 1)
3. Esophageal fistula (n = 1)
4. Coarctation of the aorta, VSD, and inguinal hernia 
(n = 1)
5. Absence of one cardiac cavity (n = 1)
6. Bilateral hip dysplasia (n = 1)
7. Polydactyly (n = 1)
8. Marked thoracic scoliosis, myelomeningocele, missing 
sacrum (caudal regression syndrome) (n = 1) [117].
Data on overall concomitant medication were avail-
able for 210 cases. Use of one or more co-medications was 
reported for 54 of these patients (25.7%). Data on exposure 
to MTX were available for 203 cases, in which 40 patients 
(19.7%) were exposed to MTX. The results of these pregnan-
cies were reported for just two cases (both live births, in one 
of them tocilizumab, MTX, and hydroxychloroquine till the 
sixth week of gestation). One case of stillbirth occurred in a 
pregnancy also exposed to MTX.
Concentration in breast milk was investigated in one 
study, in which drug concentrations of between 6 and 
60,000 ng/mL were measured up to 28 days after admin-
istration of 400 mg tocilizumab, with a peak concentration 
before day 7. The time taken to reach the maximum con-
centration (Tmax) in breast milk was calculated as 3.2 days. 
Milk to serum concentration ratios were: 0.0015, 0.00082 
and 0.0014 for three patients [119].
3.4.10  Ustekinumab
In total 54 maternal pregnancies were investigated in 22 arti-
cles. Outcomes regarding miscarriages were investigated for 
27 of these pregnancies, in which three miscarriages were 
reported (11.1%). In one case of miscarriages the treatment 
dose of ustekinumab was higher than average due to refrac-
tory Crohn’s disease [122, 124].
In 28 pregnancies investigated with regard to CMs, no 
cases were reported. Data on overall concomitant medication 
(including MTX exposure) were not available.
In one case with the last administered dose at 33 GW, 
concentration in cord blood at birth was measured (8 µg/
mL), which was higher than the drug concentration in the 
mother’s blood at the same point (4.3 µg/mL) [123].
Concentrations in breast milk were detectable in four 
cases from a total of six samples. Peak concentrations were 
between 12 and 72 h after injection (range 0.72–1.57 μg/
mL). In three cases from four samples ustekinumab was still 
detectable 48 h after injection [80].
3.4.11  Vedolizumab
In total 147 maternal pregnancies were investigated in seven 
articles. Outcomes regarding miscarriages were investigated 
for 72 of these pregnancies, in which 19 miscarriages were 
reported (26.4%).
From 110 pregnancies investigated for major CMs, two 
cases were reported (1.8%). The descriptions of these CMs 
were as follows:
1. One congenital central nervous system anomaly caused 
by agenesis of the corpus callosum and left frontal pol-
ymicrogyria. Estimated time of conception was 79 days 
after the vedolizumab infusion [132]
2. One case of congenital hypothyroidism [135].
One minor CM of hip dysplasia was also reported [131]. 
Data on overall concomitant medication were available for 
34 cases. Use of one or more co-medications was reported 
for six of these patients (17.6%). Data on exposure to MTX 
were available for ten cases, of which none were exposed 
to MTX.
From a total of 28 investigated cases regarding stillbirth, 
one case was reported to the Organization of Teratology 
Information Services (OTIS) due to fetal growth restriction 
and decreased amniotic fluid volume-induced labor (26th 
week) [132].
Drug concentrations were measured in mothers’ serum 
and breast milk in the study by Lehat et al. [133]. No sta-
tistically significant correlation was found in five patients 
with a serum concentration range of 4200–18,000 ng/mL 
and milk concentration range of 22–216 ng/mL (p = 0.11). 
Vedolizumab levels peaked at 3–4 days following infusion 
to a maximum of 480 ng/mL, and then slowly decreased 
[133]. Maternal and infants’ serum concentrations of vedoli-
zumab were also measured in five patients [131]. The range 
of drug concentrations was 1.10–14.40 μg/mL in mothers 
and 1.00–8.70 μg/mL in infants at the time of delivery [131] 
(weight-adjusted doses were not reported).
One case of a preterm born child, who developed Kawa-
saki disease with eosinophilia at 3 months, treated with cor-
ticosteroids was reported [138]. In one study in 70 children 
exposed to vedolizumab during pregnancy there were no 
malignancies reported during the first year of life [134].
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3.4.12  Other Biologics
The general conclusions of the articles, which could not 
be included in the above-mentioned subcategories, are dis-
cussed in this section.
3.4.12.1 Secukinumab Only three case reports/series 
were found in the search between 1 January 2015 until 
4 July 2019. In total five patients in these articles were 
reported, therefore this is not included in the results tables. 
Three of these cases reported spontaneous abortions and 
two resulted in live births. No information on CMs could 
be found [60, 139, 140]. One retrospective research in a 
Novartis global safety database was found on this subject; 
however, it was excluded from the final results as this was 
a research letter. Two congenital malformations from 54 
total live births and 26 spontaneous abortions from 238 
maternal pregnancies are reported. The type of CMs in 
maternal exposure was not specified with paternal expo-
sure [141].
3.4.12.2 Belimumab There were two case reports on 
using belimumab during pregnancy, which were excluded 
as they were published as research letters. Therefore, this 
is not discussed in the results tables. One Ebstein anom-
aly, one miscarriage, and one healthy birth were reported 
in a patient with systemic lupus erythematosus who was 
under belimumab treatment during three pregnancies. The 
mother was 41  years old at the time of the miscarriage 
[142]. The other case report was of a healthy birth after 
exposure to belimumab up to the 26th week of gestation. 
However, marked B-cell depletion and reduced T-cell sub-
sets were reported in the baby at birth. B cells were in 
the normal range at 4 months of age. Rotavirus vaccina-
tion 6 weeks after birth and diphtheria–tetanus–pertussis, 
haemophilus, and pneumococcus vaccinations at 3 and 
5 months of age resulted in satisfactory responses [143].
3.4.12.3 TNFα Blocker (in General, Not Specified) Some 
of the publications discussed TNF-α blockers in general 
and did not mention separate data for each biologic. As 
the outcomes could not be related to one specific biologic 
with reported data, they were not discussed in the above 
subcategories [144–154]. In general, these studies have 
shown a higher chance of flare in patients who discon-
tinue TNF-α blockers during pregnancy [144, 146]. Fur-
thermore, a higher risk of pregnancy complications and 
severe acute respiratory infections in the first year of life 
in intrauterine-exposed infants were seen (specially in 
combination therapy with thiopurines and the chronic use 
of conventional steroids) [150].
Demyelinating disorders in children exposed to TNF-α 
blockers during pregnancy were investigated in a nested 
case–control study in 399 rheumatoid arthritis patients, 
which did not report any cases of demyelinating disorders 
in these children during the follow-up period [152].
3.4.12.4 Biologics (in General, Not Specified) In some of 
the included publications the type of biologic used was 
not specified for the outcomes. In general, these studies 
did not show any abnormal outcomes in children exposed 
to biologics during pregnancy/lactation [155–167].
3.5  Risk of Bias Across Studies
The authors acknowledge that the risk of bias in total is high 
as the data are heterogenic and confounding factors could 
not be retrieved in all of the cases and from all of the stud-
ies. Biologics used in different dosages and with different 
protocols for different indications were considered together 
in this article. However, it should be remembered that this 
will not affect the recognition of causality—if any—for CMs 
and miscarriages (aims of this study).
3.6  Additional Analysis
Additional data to the above-mentioned information have 
been acquired. As different publications had different pri-
mary and secondary outcomes and because this additional 
information is scarce but still of importance, the authors see 
the necessity to summarize and present this data.
These further details for each biologic can be found in 
Tables 2, 3, and 4.
Comparison of the results regarding the rates of major 
CMs from this study with the rates in the systematic review 
of EULAR, are provided in ESM, Table 3.
4  Discussion
Available data extracted from the most recent published lit-
erature shows that the rates of miscarriages and major CMs 
in investigated biologics do not differ drastically from those 
rates in the general population (estimated as 10–20% and 
2–5.5%, respectively). In some cases the information on 
other outcomes (such as ADRs related to vaccination, pre-
term births, etc.) was not available. Despite this fact and the 
heterogeneity of the data, no new safety concerns were iden-
tified from a total of 143 investigated publications regarding 
the use of biologics during pregnancy.
Regarding the association of CMs, preterm birth, and 
birth weight with biologic use during pregnancy, a recent 
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meta-analysis by Tsao et al. also showed no increased odds 
ratios [11]. Nonetheless, it should be considered that the 
methods in the two studies are different. We have investi-
gated a broader range of studies and have summed up data 
on miscarriages (co-primary outcome) and additional sec-
ondary outcomes such as vaccination response and detect-
able drug levels during different periods. We have also 
described the pattern of reported CMs. In our systematic 
review, each biologic was considered separately. This can be 
of additional value if one specific biologic is the matter of 
interest. The study of Tsao et al. showed that the underlying 
conditions are important factors to be considered as a poten-
tial confounder for the pregnancy outcomes. In accordance 
with this conclusion, we provided detailed information on 
maternal disease baseline characteristics.
According to EMA guidelines, in order to exclude a ten- 
or twofold risk of congenital malformations for medicine 
use during pregnancy there is a need for at least 300 or 1000 
prospectively collected sets of data on pregnancies, respec-
tively. This information should be collected from exposed 
pregnancies to that particular pharmaceutical product during 
at least the first trimester [168, 169]. Based on summed up 
data in our study combined with the data from the EULAR 
study, it can be concluded that the use of adalimumab, cer-
tolizumab pegol, and infliximab during pregnancy does not 
carry a twofold increased risk of combined major CMs for 
the offspring, compared to this risk in the general population 
(estimated as 2–5.5%) [170]. The rates of major CMs from 
this study were comparable with the rates in the systematic 
review of EULAR for most of the investigated biologics, 
with some minor differences [8]. The use of adalimumab, 
certolizumab pegol, infliximab, and etanercept during preg-
nancy has been conditionally approved by the EMA recently, 
based on the results of their pregnancy registries conducted 
by pharmaceutical companies [4–7].
For several reasons the impact of medication on the inci-
dence rate of miscarriages is difficult to determine. Often in 
prospective studies women are only included when they are 
pregnant and not in the pre-conception period. In these stud-
ies early miscarriages are missed. In retrospective studies 
there is a chance of publication bias, as only women with an 
abnormal pregnancy are reported. Reliable data would only 
be available from prospective studies if women are included 
from the moment they actively try to become pregnant. Fur-
thermore, confounding by indication (some diseases cause 
more miscarriages) and confounding by concomitant medi-
cation (like MTX) can also affect the results. The results on 
miscarriages and malformations are comparable for adali-
mumab, certolizumab, and etanercept, although the transpla-
cental passage of adalimumab is extremely high.
In our study, only abatacept, tocilizumab, and ved-
olizumab show slightly higher rates for miscarriage 
compared to the incidence rate of miscarriages in the 
general population (estimated as 10–20%) [90]. It should 
be considered that the numbers of pregnancies investi-
gated for miscarriages are limited for abatacept [153] 
and vedolizumab [72]. Due to limited numbers, it cannot 
be concluded that there is a causal relationship between 
a slightly higher rate of miscarriages and the use of 
abatacept or vedolizumab. Regarding tocilizumab, high 
percentages of miscarriages can be due to publication 
bias, as this percentage is higher in retrospective data 
compared to prospective data. For tocilizumab, the high 
rate of MTX use compared to other biologics can also 
explain the higher total rate of miscarriages. Compar-
ing the results of miscarriages from this study with the 
systematic review of EULAR, the rates were comparable 
for most of the investigated biologics, with some minor 
differences as follows: rates of miscarriages for anakinra 
and rituximab were lower in our study versus the EULAR 
study (1/33 (3.1%) vs. 4/40 (10.0%) and 1/24 (4.2%) vs. 
48/210 (22.9%), respectively). However, because of the 
small number of cases, these findings remain inconclu-
sive [8].
From the secondary outcomes with acceptable reported 
sample sizes, the results were often as expected. Still 
there were some increased incidences detected, such 
as early membrane rupture, low birth weight, and pre-
term birth rates with tocilizumab therapy during preg-
nancy. Increased risk of all these three events have been 
described with the use of corticosteroids [171–173]. It 
should be noted that the rate of exposure to corticoster-
oids in the reviewed publications for tocilizumab was 
high (Table 2).
Further, serious infections rates in children exposed to 
infliximab during pregnancy were higher than expected 
(212/786 (27%)). This highlights the need for continu-
ing research evaluating the safety of infliximab on vari-
ous maternal infections and infections in offspring. Dif-
ferent studies have shown that combination therapy with 
anti-TNF α and thiopurines during pregnancy is associ-
ated with a higher rate of infections in offspring when 
compared to monotherapy with anti-TNF α [42, 136]. The 
overall rate of exposure to thiopurines for infliximab in our 
systematic review was 39.2%, higher than other biologics, 
which can explain the higher rates of serious infections in 
this group. Additionally, most of the reported infections 
were from the study by Truta et al., which reported acute 
respiratory infections, without differentiating the serious 
infections from non-serious infections. In this study, data 
acquisition was done retrospectively, which increases 
the chance of publication bias. Furthermore, in most of 
the pregnancies in this study infliximab was discontin-
ued 90 days or less before delivery, therefore it is more 
likely that an immunoglobulin with a high affinity for the 
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neonatal Fc receptor (in this case infliximab) transfers 
through the placenta and reaches the fetus [111, 174].
From the available data on other secondary outcomes 
some subcategories may give the impression of an 
increased incidence compared to the normal population 
such as placental abnormality rate for infliximab and ved-
olizumab (1/6 (16.7%) and 2/4 (50.0%), respectively), low 
birth-weight rate for anakinra (6/19 (31.6%)), anti-drug 
antibodies at birth (4/51 (7.8%)), and detectable drug lev-
els at the 9th (7/46 (15.2%)) and 12th months of age (3/46 
(6.5%)), in children exposed to infliximab during preg-
nancy. However, conclusions should be drawn with caution 
regarding the above-mentioned increased incidences.
4.1  Limitations
The protocol of this study was recorded retrospectively 
in PROSPERO (after conducting the first search in the 
databases). Another limitation of this study is that the 
small sample sizes and small numbers of reports involved 
in some outcomes (especially secondary outcomes) make 
interpretations based on acquired results uncertain. Fur-
thermore, type of disease, disease activity during preg-
nancy, extent of systemic inflammation, and organ involve-
ment, co-morbidities, and concomitant drug therapy could 
also have contributed to negative outcomes. In this study 
all types of rheumatologic, gastroenteric, and dermato-
logic biologics were considered together as the types of 
biologics used in the management of these diseases over-
lap. All the increased incidences should be further inves-
tigated and confirmed in future studies, aiming to collect 
prospective data.
5  Conclusions
Based on the results of our study it is likely that adalimumab, 
certolizumab pegol, and etanercept conceivably can be pre-
scribed safely during pregnancy, especially considering the 
negative effects of active disease on mothers, pregnancy out-
comes, and the children. Regarding infliximab, high rates of 
infections in children have been detected, mainly from one 
study [111], and a more conservative approach, especially 
in combination therapy with thiopurines, is recommended. 
Discontinuation before the third trimester may decrease the 
chance of infections in offspring. Further, the risks of using 
abatacept, anakinra, canakinumab, golimumab, rituximab, 
tocilizumab, ustekinumab, and vedolizumab are not well 
known and available data are scarce in this regard. This 
study confirms the previous literature reviews carried out on 
use of biologics during pregnancy in autoimmune diseases.
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